A Safety Study of Eptifibatide in Patients With Sickle Cell Disease

Stopped early · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Sickle Cell Disease

In brief

This study will evaluate the safety of eptifibatide in sickle cell patients and how well it works during the course of painful crises. The overall hypothesis that we seek to test is that increased platelet activation and the resultant inflammatory responses are important contributors to the problems of sickle cell disease. Sickle cell disease has been referred to both as a condition associated with increased risk of blood clots and increased inflammation. A painful crisis represents the most common cli nical problem in sickle cell disease, but the treatment of these crises remains inadequate.

Key facts

Study ID

NCT00834899

Run by

University of North Carolina, Chapel Hill

People needed

13

Starts

2009-01-01

Expected to finish

2012-03-01

Last updated by the study team

2013-06-27

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age between 18 and 55 years
• Have confirmed diagnosis of sickle cell anemia or sickle beta zero thalassemia
• Have a serum creatinine </= 1.2 mg/dl
• Have serum transaminase values < 3 times upper limits of normal
• Have a platelet count >/= 150 x 10\^9/L
• Have normal baseline coagulation profile
• Sudden onset of pain involving one or more sites and typical of usual pain episodes
• Have adequate intravenous access
• Be able to understand the requirements of the study and be willing to give informed consent
• Women of child-bearing age must be practicing (and will continue to practice for the course of the study) an adequate method of contraception (oral contraception, depo-provera, bilateral tubal ligation or barrier method)

You may not qualify if…

• Have a baseline hemoglobin < 6.0 gm/dl
• Have a history of major gastrointestinal bleeding or a bleeding diathesis
• Have an ongoing episode of acute chest syndrome
• Have a past history of clinically overt stroke(s)
• Have severe hypertension (systolic blood pressure > 200mmHg and/or diastolic BP >110mmHg) not adequately controlled on hypertensive medication
• Have had major surgery within the six weeks preceding enrollment
• Are pregnant or breastfeeding
• Are on chronic anticoagulation or antiplatelet (including non-steroidal anti-inflammatory drugs) therapy
• Have a history of metastatic cancer
• Are on a chronic transfusion program or have received a blood transfusion in the prior 8 weeks
• Have a positive urine toxicology screen for phencyclidine, cocaine or amphetamines.
• Have a history of alcohol abuse
• Have received any investigational drugs within the past 4 weeks.

Where it is running

• University of North Carolina — Chapel Hill, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.